|本期目录/Table of Contents|

[1]金 怡,郑 怡,张航瑜,等.肠道微生态对肿瘤免疫治疗的影响[J].传染病信息,2018,04:372-375.
 JIN Yi,ZHENG Yi,ZHANG Hang-yu,et al.Effects of intestinal microbiota on cancer immunotherapy[J].Infectious Disease Information,2018,04:372-375.



综  述


Effects of intestinal microbiota on cancer immunotherapy
金 怡郑 怡张航瑜赵 鹏涂晓璇吴 伟刘璐璐方维佳
317100 台州,三门县人民医院中西医结合科(金怡); 310003 杭州,浙江大学附属第一医院肿瘤细胞生物治疗中心 (郑怡、张航瑜、赵鹏、涂晓璇、吴伟、刘璐璐、方维佳)
JIN Yi ZHENG Yi ZHANG Hang-yu ZHAO Peng TU Xiao-xuan WU Wei LIU Lu-lu FANG Wei-jia*
Department of Traditional Chinese Medicine and Western Medicine, Peoples's Hospital of Sanmen County, Taizhou 317100, China
intestinal microbiota immune immune checkpoint inhibitors cancer immunotherapy
近年来,研究表明肠道微生态对肿瘤免疫治疗有重要的影响,肠道微生态与各类免疫检查点抑制剂如抗细胞 毒性T 淋巴细胞相关抗原4 抗体、抗程序性细胞死亡蛋白1 抗体以及抗程序性细胞死亡蛋白配体1 抗体的疗效密切相关。 本文回顾分析了相关基础及临床研究的最新进展,发现诸如Akkermansia muciniphila、双歧杆菌等重要有益菌可提升肿瘤免 疫治疗的效果并作为生物标志物。因此,推测多样化的肠道微生态有利于维持机体内环境稳定,肠道微生态的合理调控可提 高肿瘤免疫治疗效果,并减轻不良反应。
Recent studies indicate that intestinal microbiota plays an important role in cancer immunotherapy. Intestinal microbiota is closely related to the treatment effect of immune checkpoint inhibitors targeting cytotoxic T lymphocyte associated antigen 4, programmed cell death protein 1 and programmed cell death protein 1 ligand. Our study analyzes recent progress of related basic and clinical studies and finds that several bacteria such as Akkermansia muciniphila and Bifidobacterium can improve cancer immunotherapy efficacy and may act as a biomarker. Therefore, we conclude that diversified intestinal microbiota can maintain the stability of the internal environment, and equitable regulation of intestinal microbiota can improve the efficacy of cancer immunotherapy and reduce adverse reactions.


[1] Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion [J]. Science, 2011, 331(6024):1565-1570.
[2] Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma[J]. N Engl J Med, 2015, 372(21):2006-2017.
[3] Chen DS, Mellman I. Oncology meets immunology: the cancerimmunity cycle[J]. Immunity, 2013, 39(1):1-10.
[4] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4):252-264.
[5] Hodi FS, O'Day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma.[J]. N Engl J Med, 2010, 363(8):711-723.
[6] Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma[J]. N Engl J Med, 2013, 369(2):134-144.
[7] Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies[J]. Cancer Cell, 2018, 33(4):581-598.
[8] Ivanov II, Littman DR. Modulation of immune homeostasis by commensal bacteria[J]. Curr Opin Microbiol, 2011, 14(1):106- 114.
[9] Cebula A, Seweryn M, Rempala GA, et al. Thymus-derived regulatory T cells control tolerance to commensal microbiota[J]. Nature, 2013, 497(7448):258.
[10] Wesemann DR, Portuguese AJ, Meyers RM, et al. Microbial colonization influences early B-lineage development in the gut lamina propria[J]. Nature, 2013, 501(7465):112-115.
[11] Smith PD, Smythies LE, Shen R, et al. Intestinal macrophages and response to microbial encroachment[J]. Mucosal Immunol, 2011, 4(1):31-42.
[12] Ganal SC, Sanos SL, Kallfass C, et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota[J]. Immunity, 2012, 37(1):171-186.
[13] Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity[J]. Gut Microbes, 2012, 3(1):4-14.
[14] Weng M, Walker WA. The role of gut microbiota in programming the immune phenotype[J]. J Dev Orig Health Dis, 2013, 4(3):203-214.
[15] Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy[J]. CA Cancer J Clin, 2017, 67(4):326-344.
[16] Zitvogel L, Daillere R, Roberti MP, et al. Anticancer effects of the microbiome and its products[J]. Nat Rev Microbiol, 2017, 15(8):465-478.
[17] Dai Z, Coker OO, Nakatsu G, et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers[J]. Microbiome, 2018, 6(1):70.
[18] Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy [J]. Science, 2015, 350(6264):1084-1089.
[19] Veglia F, Gabrilovich DI. Dendritic cells in cancer: the role revisited[J]. Curr Opin Immunol, 2017, 45:43-51.
[20] Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J]. Science, 2015, 350(6264):1079-1084.
[21] Uribe-Herranz M, Bittinger K, Rafail S, et al. Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12[J]. JCI Insight, 2018, 3(4):pii94952.
[22] Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors [J]. Science, 2018, 359(6371):91-97.
[23] Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018, 359(6371):97-103.
[24] Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer[J]. Mol Cell Endocrino, 2014, 382(1):673-682.
[25] 曲建慧,张翠红,李若然,等. 肝细胞癌免疫治疗的现状与 挑战[J]. 传染病信息,2016,29(4):193-197.
[26] Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients [J]. Science, 2018, 359(6371):104-108.
[27] Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab[J]. Ann Oncol, 2017, 28(6):1368-1379.
[28] Di Giacomo AM, Ascierto PA, Queirolo P, et al. Three-year followup of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study[J]. Ann Oncol, 2015, 26(4):798- 803.
[29] Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpointblockade- induced colitis[J]. Nat Commun, 2016, 7:10391.
[30] Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial[J]. Lancet Oncol, 2016, 17(11):1558-1568.
[31] Zitvogel L, Galluzzi L, Viaud S, et al. Cancer and the gut microbiota: an unexpected link[J]. Sci Transl Med, 2015, 7(271):271pS1 .
[32] Laffin M, Madsen KL. Fecal microbial transplantation in inflammatory bowel disease: a movement too big to be ignored[J]. Clin Pharmacol Ther, 2017, 102(4):588-590.
[33] Zitvogel L, Ayyoub M, Routy B, et al. Microbiome and anticancer immunosurveillance.[J]. Cell, 2016, 165(2):276-287.
[34] Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy[J]. Annu Rev Immunol, 2013, 31(1):51-72.
[35] Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer[J]. Science, 2017, 358(6369):1443-1448.
[36] Kaderbhai C, Richard C, Fumet JD, et al. Antibiotic use does not appear to influence response to nivolumab[J]. Anticancer Research, 2017, 37(6):3195.
[37] Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J]. Science, 2013, 342(6161):971-976.
[38] Foxxorenstein AE, Chey WD. Manipulation of the gut microbiota as a novel treatment strategy for gastrointestinal disorders[J]. Am J Gastroenterol Suppl, 2012,1(1):41-46.
[39] Satlin MJ, Vardhana S, Soave R, et al. Impact of prophylactic levofloxacin on rates of bloodstream infection and fever in neutropenic patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation[J]. Biol Blood Marrow
[40] Lopetuso LR, Petito V, Scaldaferri F, et al. Gut microbiota modulation and mucosal immunity: focus on rifaximin[J]. Mini Rev Med Chem, 2015, 16(3):179-185.


[ 基金项目 ] 浙江省重大科技专项(2017C03028) [ 作者单位] 317100 台州,三门县人民医院中西医结合科(金怡); 310003 杭州,浙江大学附属第一医院肿瘤细胞生物治疗中心 (郑怡、张航瑜、赵鹏、涂晓璇、吴伟、刘璐璐、方维佳) [ 通信作者 ] 方维佳,E-mail: weijiafang@zju.edu.cn
更新日期/Last Update: 2018-09-08